Heijerman H G, Lamers C B, Bakker W, Dijkman J H
Department of Pulmonology, Leyenburg Hospital, The Hague, The Netherlands.
Dig Dis Sci. 1993 Jan;38(1):1-6. doi: 10.1007/BF01296765.
Pancreatic function tests were performed in 11 adult cystic fibrosis (CF) patients with a fecal fat excretion of more than 10% during treatment with pancrease 2 capsules three times a day. These tests included urinary p-aminobenzoic acid (PABA) excretion, fasting serum trypsin and pancreatic polypeptide (PP), and glucose and insulin in fasting and postprandial serum. Subsequently, the patients entered a double-blind placebo-controlled crossover study to assess the effect of gastric acid inhibition by 20 mg omeprazole on fecal fat excretion. Adjunct therapy with omeprazole resulted in a reduction of fecal fat excretion in patients with residual pancreatic function. This improvement showed significant positive correlations with urinary PABA excretion and the increase in serum PP after the meal (P < 0.02 and P < 0.05), but not with the other parameters studied. Therefore, the addition of omeprazole to pancrease is most successful in CF patients with residual pancreatic function, determined by urinary PABA excretion or incremental PP.
对11名成年囊性纤维化（CF）患者进行了胰腺功能测试，这些患者在接受每天三次、每次2粒胰酶胶囊治疗期间，粪便脂肪排泄量超过10%。这些测试包括尿对氨基苯甲酸（PABA）排泄、空腹血清胰蛋白酶和胰多肽（PP），以及空腹和餐后血清中的葡萄糖和胰岛素。随后，患者进入一项双盲安慰剂对照交叉研究，以评估20毫克奥美拉唑抑制胃酸对粪便脂肪排泄的影响。奥美拉唑辅助治疗使残余胰腺功能患者的粪便脂肪排泄量减少。这种改善与尿PABA排泄以及餐后血清PP的增加呈显著正相关（P<0.02和P<0.05），但与其他研究参数无关。因此，对于通过尿PABA排泄或PP增量确定为具有残余胰腺功能的CF患者，在胰酶治疗中添加奥美拉唑最为有效。
